showed a trendP = 0.070
Although not statistically significant, patients treated with anti-PD-1 antibodies showed a trend toward improved RFS compared to those without adjuvant therapy (HR 0.72, 95% CI 0.21–1.03, P = 0.070).
Although not statistically significant, patients treated with anti-PD-1 antibodies showed a trend toward improved RFS compared to those without adjuvant therapy (HR 0.72, 95% CI 0.21–1.03, P = 0.070).